What Researchers Did
This review examined how hyperbaric oxygen (HBO2) mitigates immune reactions involved in allograft transplant rejection, supporting its potential use as an adjunct in tissue transplantation.
What They Found
Researchers found that HBO2 exhibits immunosuppressive effects, including decreased production of IL-1 and CD4 cells, and an increased percentage and absolute number of CD8 cells. HBO2 also normalizes cell-bound immunity, decreases serum immune complexes, and alters MHC class I expression to become undetectable, supporting its use in various tissue transplants like rabbit ear grafts and liver transplants.
What This Means for Canadian Patients
Canadian patients undergoing organ or tissue transplantation might benefit from hyperbaric oxygen (HBO2) as an adjunct therapy to reduce immune rejection. This could potentially improve transplant success rates and long-term graft survival, offering a new avenue for managing post-transplant complications.
Canadian Relevance
This review does not indicate any direct Canadian connection or involvement in the research.
Study Limitations
As a review, this study synthesizes existing literature but does not present new primary human clinical trial data on HBO2 for transplant rejection.